Isoleucine

Isoleucine

1. Identity

Chemical and Biochemical Names

Isoleucine (symbol Ile or I) is an α-amino acid used in the biosynthesis of proteins. It contains an α-amino group, an α-carboxylic acid group, and a hydrocarbon side chain with a branch — a central carbon atom bound to three other carbon atoms. It is classified as a non-polar, uncharged (at physiological pH), branched-chain, aliphatic amino acid. The form found in nature exists as (2S,3S)-2-amino-3-methylpentanoic acid, and only this stereoisomeric form is involved in the synthesis of proteins. Isoleucine's molecular formula is C₆H₁₃NO₂. Its standard one-letter abbreviation is I, and its three-letter abbreviation is Ile.

Although isoleucine and leucine share the same chemical formula (C₆H₁₃NO₂), they are structural isomers. The key difference is in the arrangement of their side chains: isoleucine has a sec-butyl group attached by its second carbon. Like leucine and valine, isoleucine has large aliphatic hydrophobic side chains. Its molecules are rigid, and its mutual hydrophobic interactions are important for the correct folding of proteins; these amino acids tend to be located inside of the protein molecule.

Discovery

Isoleucine was first isolated in 1904 from fibrin, a protein involved in blood-clot formation. First identified and isolated in the early twentieth century, BCAAs — including isoleucine — have since been the focus of extensive research, especially due to their increasing importance in health and disease.

Classification as an Essential Amino Acid

Isoleucine is essential in humans, meaning the body cannot synthesize it. Essential amino acids are necessary in the human diet. Isoleucine is one of the three branched-chain amino acids (BCAAs), alongside leucine and valine. Muscular proteins are dominantly built with BCAAs, which make up 20% to 25% of all amino acids in dietary proteins and play primary roles in muscular function.

Genetic Encoding

Isoleucine is encoded by the codons AUU, AUC, and AUA.

Natural Sources

Foods with high amounts of isoleucine include eggs, soy protein, seaweed, turkey, chicken, lamb, cheese, and fish. Rich sources include eggs, chicken, pork, mutton, pulses, soya beans, cottage cheese, milk, piyal seeds, cashew nuts, and cereal grains. In one analysis of dietary patterns, meat and meat products contributed 41.3% of isoleucine intake. The other main food sources were grain products and milk and dairy products; specifically, processed red and poultry products and bread products were the main food group sources.

In plants, isoleucine can be synthesized from threonine and methionine, and in plants and bacteria it is synthesized from a pyruvate employing leucine biosynthesis enzymes. While isoleucine is not synthesized in animals, in plants and microorganisms it is synthesized via several steps starting from pyruvic acid.

Commercial Preparation and Forms

Biosynthesis of isoleucine for commercial purposes is commonly achieved through microbial fermentation. Engineered strains of bacteria, such as Corynebacterium glutamicum or Escherichia coli, are cultivated in controlled environments to produce high yields. These microorganisms are optimized to convert glucose or other carbon sources into isoleucine using metabolic engineering techniques. Fermentation-based production is widely employed in the supplement industry, where large-scale fermentation tanks allow for efficient production with high purity. Isoleucine is commercially available as a free-form amino acid powder (L-isoleucine), as a component of BCAA combination supplements (typically combined with leucine and valine), and in intravenous amino acid solutions used clinically. Nutritional supplements containing BCAAs including isoleucine can be administered orally or intravenously, and available products differ in terms of BCAA content.

2. Traditional and Historical Use

Isoleucine as an isolated chemical entity has no traditional use predating modern biochemistry — it is not a botanical herb or traditional medicinal preparation but rather a constituent of dietary protein identified in the early twentieth century. It is an amino acid present in most common proteins, sometimes comprising 2 to 10 percent by weight; it was first isolated in 1904 from fibrin, a protein involved in blood-clot formation.

Traditional dietary practices that were rich in protein — including meat-based diets in hunter-gatherer societies, legume consumption in agricultural civilizations, and dairy-centered diets in pastoral cultures — inherently provided dietary BCAA including isoleucine, although these sources were consumed as whole foods rather than isolated amino acids. The clinical and scientific investigation of isoleucine as a distinct biological entity and dietary supplement belongs entirely to the modern era of biochemistry and nutritional science beginning in the twentieth century. BCAAs have been the focus of extensive research especially due to their increasing importance in health and disease. The use of BCAA preparations (including isoleucine) in clinical medicine — particularly for hepatic encephalopathy and surgical/critical-care nutrition — began in the latter decades of the twentieth century and has been evaluated in formal clinical trials. Several clinical studies evaluated the role of BCAAs in the treatment and prevention of hepatic encephalopathy (HE) in cirrhotic subjects, and in the early 1980s a randomized study evaluated the effect of BCAAs in protein-intolerant cirrhotic patients.

3. Key Constituents and Active Compounds

The Isoleucine Molecule

Isoleucine is both a glucogenic and a ketogenic amino acid. After transamination with alpha-ketoglutarate, the carbon skeleton is oxidized and split into propionyl-CoA and acetyl-CoA. Propionyl-CoA is converted into succinyl-CoA, a TCA cycle intermediate which can be converted into oxaloacetate for gluconeogenesis (hence glucogenic). In mammals, acetyl-CoA cannot be converted to carbohydrate but can be either fed into the TCA cycle or used in the synthesis of ketone bodies (hence ketogenic) or fatty acids.

Catabolic Intermediates and Metabolites

The two consecutive initial reactions of BCAA catabolism are catalyzed by branched chain aminotransferase (BCAT) and branched chain α-keto acid dehydrogenase (BCKDH). BCAT transfers the amino group of BCAAs to 2-ketoglutarate, resulting in corresponding branched chain 2-keto acids (BCKAs) and glutamate. BCKDH then performs an oxidative decarboxylation of BCKAs, producing their coenzyme A-conjugates and NADH. BCAT2 in skeletal muscle dominantly catalyzes the transamination of BCAAs. Low BCAT activity in the liver reduces the metabolization of BCAAs, but the abundant presence of BCKDH promotes the metabolism of muscle-derived BCKAs, which leads to the production of glucose and ketone bodies.

Although catabolism of each BCAA shares several steps, the intermediate and final products of each BCAA are distinct. For example, 3-hydroxy-isobutyrate is a valine-specific catabolite that regulates trans-endothelial fatty acid transport. Isoleucine has its own distinct catabolic intermediates that are separate from those of leucine and valine.

Hepatic vs. Peripheral Metabolism

Unlike some other amino acids, BCAAs are not extensively metabolized in the liver. BCAT activity in the liver is low and thus BCAAs bypass significant regulation in this organ before entering the bloodstream, where they become available for uptake by different tissues. BCAAs are rarely metabolized by the liver because the expression of BCAT, which acts to remove amino groups in the first step of any amino acid catabolism, is very low. This metabolic property allows dietary BCAAs to be delivered effectively in intact forms to muscular tissues.

4. Mechanisms of Action

Protein Synthesis and mTOR Signaling

It is widely established that BCAAs are not only elementary components for building muscle tissue but also participate in increasing protein synthesis. BCAAs including isoleucine regulate many key signaling pathways, the most classic of which is the activation of the mTOR (mechanistic target of rapamycin) signaling pathway, which connects many diverse physiological and metabolic roles. Although most research has investigated the physiological roles of the BCAAs in combination, evidence is now emerging that the three BCAAs may have distinct effects on molecular processes. The three BCAAs differentially activate mTORC1, a key regulator of many metabolic processes.

Glucose Uptake and Glucose Transport

Recent years have witnessed developments showing that BCAAs, especially isoleucine, play a major role in enhancing glucose consumption and utilization by up-regulating intestinal and muscular glucose transporters. Studies in animal models have shown that isoleucine up-regulates the protein expressions of GLUT1 (in red muscle), GLUT4 (in red and white muscle), SGLT-1 (in the duodenum, jejunum and ileum), and GLUT2 (in duodenum and jejunum).

Oral administration of isoleucine decreased plasma glucose levels by 20% and significantly increased muscle glucose uptake by 71% without significant elevation of the plasma insulin level compared with controls at 60 minutes after administration. Isoleucine plays an important role in the improvement of glucose metabolism as evidenced by insulin-independent glucose uptake in vitro. Glucose uptake in the skeletal muscles of rats administered isoleucine was 73% greater than in controls, while AMP-kinase alpha1 activity was not affected. However, isoleucine significantly decreased AMPK alpha2 activity, and this decrease was thought to be related to decreases in AMP content and the AMP:ATP ratio.

Immune and Antimicrobial Functions

Studies have shown that isoleucine can regulate innate and adaptive immunity by inducing the expression of β-defensin, an important antimicrobial peptide that can enhance the host's defense ability. Isoleucine has also been shown to promote the expression of GLUT4, a glucose transporter, thereby enhancing glucose uptake in muscle tissue. As a branched-chain amino acid, isoleucine is rapidly metabolized in immune cells to provide local energy support, which is crucial for the rapid proliferation and activation of immune cells.

AMPK and Insulin Signaling Pathways

BCAAs, including isoleucine, perform functions including lipid metabolism, gluconeogenesis, and serving as nitrogen donors in different biological processes. Their actions mainly involve several key metabolic pathways such as mTORC1, AMP-activated protein kinase (AMPK), and general control non-derepressible (GCN) 2, as well as insulin signaling.

5. Scientific Evidence by Area of Use

5.1 Skeletal Muscle Metabolism and Exercise Performance

Branched-chain amino acids including isoleucine are widely popular in sports nutrition products. Their major marketing appeal derives from allegations that BCAA intake combined with resistance physical exercise stimulates muscle protein synthesis. This long-standing claim (over 35 years) is based on cellular and animal model studies reporting enhanced anabolic intracellular signaling in response to BCAA intake. However, evidence supporting the efficacy of isolated BCAA intake for muscle hypertrophy in humans is equivocal.

Branched-chain amino acids valine, leucine, and isoleucine are widely popular among products with ergogenic claims. Their major marketing appeal derives from allegations that BCAA intake combined with resistance physical exercise stimulates muscle protein synthesis. Evidence supporting the efficacy of BCAAs alone for muscle hypertrophy in humans is somewhat equivocal.

Isoleucine is required for muscle protein synthesis, and it may help to reduce post-exercise muscle soreness and markers of muscle damage when taken as part of a BCAA supplement. However, whether isoleucine holds any special merit as a supplement on its own is unclear.

Leucine, isoleucine, and valine, the BCAAs, make up about one-third of muscle protein. Of these, leucine has been the most thoroughly investigated because its oxidation rate is higher than that of isoleucine or valine. Most human clinical trials in this area have tested BCAA formulations collectively rather than isoleucine in isolation, making it impossible to isolate the specific contribution of isoleucine alone. The evidence for muscle hypertrophy from isolated BCAA supplements (as distinct from complete protein sources) remains preliminary in human studies.

5.2 Glucose Metabolism and Insulin Sensitivity

One study evaluated the effect of isoleucine on glucose uptake and oxidation in fasted rats. Oral administration of isoleucine decreased the plasma glucose level by 20% and significantly increased muscle glucose uptake by 71% without significant elevation of the plasma insulin level. Furthermore, expiratory excretion of ¹⁴CO₂ from labeled glucose was increased by 19% in isoleucine-administered rats compared with controls. Isoleucine also decreased AMP levels in the liver but did not affect hepatic glycogen synthesis. Under insulin-free conditions, isoleucine significantly inhibited glucose production when alanine was used as a glucogenic substrate in isolated hepatocytes. These findings are from animal studies.

In a human study, when isoleucine was ingested with glucose, insulin increased and the maximum concentration was 43% higher than following ingestion of glucose alone; the glucose concentration increase was less and it decreased more rapidly following isoleucine plus glucose compared to glucose alone. This effect was independent of insulin and was not AMP kinase-mediated. The mechanisms involved remain to be determined; whether the isoleucine effect is due directly to the absorbed amino acid and/or is mediated through stimulation of a gut incretin hormone also remains to be determined. This study was conducted in non-diabetic subjects and is limited in scope.

Elevated levels of BCAAs including isoleucine have been associated with insulin resistance in some studies. The relationship between BCAA levels and insulin resistance is complex and may be influenced by factors such as obesity and genetic predisposition.

5.3 Isoleucine, Obesity, and Metabolic Health

Research in animal models has shown that reducing isoleucine or valine rapidly restores metabolic health to diet-induced obese mice, and variation in dietary isoleucine levels appears to help explain body mass index differences in humans. These results reveal isoleucine as a key regulator of metabolic health and the adverse metabolic response to dietary BCAAs. Low-protein diets promote metabolic health in rodents and humans, and the benefits of low-protein diets are recapitulated by specifically reducing dietary levels of BCAAs. Each BCAA has distinct metabolic effects: a low isoleucine diet reprograms liver and adipose metabolism, increasing hepatic insulin sensitivity and ketogenesis, and increasing energy expenditure.

Consumption of isoleucine is positively correlated with body mass index in humans, and reducing dietary levels of isoleucine rapidly improves the metabolic health of diet-induced obese mice. Reducing dietary levels of isoleucine protects mice of both sexes from the deleterious metabolic effects of a Western diet, while increasing dietary levels of isoleucine impairs aspects of metabolic health. These findings are primarily from animal models, with the human correlational data supporting the association but not proving causality.

Elevated fasting blood BCAA concentrations are considered a metabolic hallmark of obesity, insulin resistance, dyslipidaemia, nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. However, since increased BCAA levels are observed both in metabolically healthy and obese subjects, a question of whether BCAAs are mechanistic drivers of insulin resistance or only markers of metabolic dysregulation remains open.

5.4 BCAAs (Including Isoleucine) in Hepatic Encephalopathy and Liver Disease

BCAAs including leucine, isoleucine, and valine have been shown to affect gene expression, protein metabolism, apoptosis and regeneration of hepatocytes, and insulin resistance. In patients with advanced chronic liver disease, BCAA concentrations are low, whereas the concentrations of aromatic amino acids such as phenylalanine and tyrosine are high — conditions that may be closely associated with hepatic encephalopathy (HE).

A Cochrane systematic review evaluated 11 randomized clinical trials on BCAA versus control interventions for hepatic encephalopathy. The review found 16 randomized clinical trials including 827 participants with hepatic encephalopathy classified as overt (12 trials) or minimal (four trials). Eight trials assessed oral BCAA supplements and seven assessed intravenous BCAA. Control groups received placebo/no intervention, diets, lactulose, or neomycin. In 15 trials, all participants had cirrhosis. Seven trials were classified as low risk of bias and nine as high risk of bias (mainly due to lack of blinding or for-profit funding).

The analyses showed that BCAA had a beneficial effect on hepatic encephalopathy. No effect was found on mortality, quality of life, or nutritional parameters, but additional trials are needed to evaluate these outcomes. Additional randomized clinical trials are needed to determine the effect of BCAA compared with interventions such as non-absorbable disaccharides, rifaximin, or other antibiotics. The evidence suggests BCAAs reduce hepatic encephalopathy, but the certainty of evidence is low. Whether BCAAs compared with controls have any effect on all-cause mortality, nausea and diarrhoea, albumin, and nitrogen balance is unknown because of very low-certainty evidence.

One large clinical trial, referenced in the hepatology literature, conducted by Muto et al., was a multicenter, randomized, nutrient-intake–controlled trial on oral BCAA supplementation at 12 g/d for 2 years versus non-BCAA–supplemented diet therapy, conducted in 646 patients with cirrhosis. The primary endpoint was a composite of death by any cause, development of liver cancer, rupture of esophageal varices, or progression of hepatic failure (event-free survival).

5.5 Circulating BCAAs, Type 2 Diabetes, and Cardiovascular Disease

Several human epidemiological studies have demonstrated an association between elevated circulating BCAAs and the prevalence or development of obesity, type 2 diabetes, hypertension, atherosclerotic cardiovascular disease, and heart failure. BCAAs including isoleucine, leucine, and valine have been associated with cardiometabolic risk factors in cross-sectional studies, including anthropometric measures of excess body weight, impaired fasting glucose, insulin resistance, elevated blood pressure, dyslipidemia, and indicators of coronary artery disease.

Circulating BCAAs have been consistently observed as strongly associated with type 2 diabetes, and compelling evidence supports a causal role of dysfunctional BCAA metabolism in the development of insulin resistance and T2D. Mutations in the genes responsible for BCAA catabolism are involved in rare inherited disorders, and aberrant regulation of their enzymatic activities is associated with major metabolic disorders such as diabetes, cardiovascular disease, and cancer.

A study found that blood levels of leucine and valine correlated with decreased mortality, whereas blood levels of isoleucine correlated with increased mortality. It must be emphasized that these associations are observational and do not establish that dietary isoleucine intake is itself a cause of disease in healthy individuals; rather, impaired BCAA catabolism in already-diseased metabolic tissue is likely a major driver of elevated circulating BCAAs.

5.6 Isoleucine and Immune Function

Studies have shown that isoleucine can regulate innate and adaptive immunity by inducing the expression of β-defensin, an important antimicrobial peptide that can enhance the host's defense ability. Direct clinical human evidence for isoleucine supplementation improving immune outcomes is limited; most evidence in this area comes from animal models and in vitro cell studies. It is widely known that BCAAs including isoleucine participate in increasing protein synthesis and possess other metabolic roles. The immune function evidence base for isoleucine specifically (as opposed to BCAAs collectively) remains preliminary.

6. Body Systems and Health Areas

• Musculoskeletal system: BCAAs constitute 35% of the necessary amino acids in muscle and serve as fundamental components for tissue protein, in addition to possessing other metabolic roles. Isoleucine is a structural precursor for muscle proteins and participates in post-exercise recovery processes within BCAA formulations.
• Endocrine/metabolic system: Isoleucine participates in the regulation of glucose metabolism. It promotes insulin-independent glucose uptake in skeletal muscle and modulates hepatic gluconeogenesis, as demonstrated in animal and preliminary human studies.
• Hepatic system: BCAAs including leucine, isoleucine, and valine have been shown to affect gene expression, protein metabolism, apoptosis and regeneration of hepatocytes, and insulin resistance. BCAA supplementation has been evaluated clinically for management of hepatic encephalopathy in cirrhosis.
• Immune system: Isoleucine contributes to innate immunity through its role in stimulating β-defensin expression and providing energy substrate for immune cell proliferation, based on preclinical evidence.
• Nervous system / Brain: In the context of hepatic encephalopathy, BCAAs including isoleucine compete with aromatic amino acids for transport across the blood-brain barrier, potentially modulating neurotransmitter balance. The BCAA play an important part in the generation of muscles and of the signalling chemicals in the brain.
• Cardiovascular and metabolic risk: BCAAs including isoleucine can serve as predictive risk biomarkers for a variety of disorders, including obesity and T2D. However, chronic elevation of BCAAs is associated with metabolic diseases such as obesity, type 2 diabetes, and metabolic-associated fatty liver disease.
• Hematopoietic system: As a key player in protein synthesis and energy metabolism, isoleucine contributes to the production of hemoglobin.

7. Dosage Forms and Dosages Reported in Studies

Recommended Dietary Allowance

The Food and Nutrition Board of the U.S. Institute of Medicine has set Recommended Dietary Allowances (RDAs) for essential amino acids. For adults 19 years and older, 19 mg of isoleucine per kg of body weight is required daily. The recommended daily allowance (RDA) of isoleucine established by the Institute of Medicine is 19 mg of isoleucine per kilogram of bodyweight (mg/kg) daily.

Tolerable Upper Intake Level

For the remaining amino acids, there have been no new systematic clinical studies conducted. Among the remaining indispensable amino acids, there are no studies available for isoleucine, valine, and threonine in healthy individuals that would allow formal determination of a tolerable upper intake level (UL).

Doses Used in Clinical and Research Settings

• Hepatic encephalopathy (clinical trial, oral): In the large multicenter trial by Muto et al., BCAA supplementation was administered orally at 12 g/day for 2 years in patients with cirrhosis.
• Glucose lowering (animal study): In rats, isoleucine administered orally at 0.3 g/kg, 30 minutes before 2 g of glucose, attenuated the blood glucose response. Smaller doses had no effect.
• General BCAA supplementation (safety review): Clinical studies at 5–20 g/day of BCAAs for up to one year have not produced significant adverse events in healthy adults.
• MSUD management (pediatric, intravenous): In pediatric MSUD patients during metabolic decompensation, isoleucine and valine supplementation was titrated to plasma concentrations at doses of 20–120 mg/kg/day.

8. Safety Considerations and Interactions

General Safety Profile

BCAAs including isoleucine carry GRAS (Generally Recognized As Safe) status from the FDA. Clinical studies at 5–20 g/day of BCAAs for up to one year have not produced significant adverse events in healthy adults.

Gastrointestinal Effects

BCAA supplementation did not increase the risk of serious adverse events, but was associated with nausea and diarrhoea in the Cochrane review population of patients with hepatic encephalopathy.

Maple Syrup Urine Disease (MSUD)

Maple syrup urine disease (MSUD) is caused by decreased activity of the branched-chain alpha-ketoacid dehydrogenase complex (BCKD), the second enzymatic step in the degradative pathway of the branched-chain amino acids, which includes leucine, isoleucine, and valine. MSUD is an absolute contraindication for unsupervised BCAA supplementation. MSUD is a rare genetic disorder caused by deficient activity of the branched-chain α-keto acid dehydrogenase (BCKDH) enzyme complex — the enzyme responsible for the second step of BCAA catabolism. Without functional BCKDH, leucine, isoleucine, valine, and their keto-acid metabolites accumulate to neurotoxic levels in blood and cerebrospinal fluid. Paradoxically, in the managed clinical treatment of MSUD, treatment consists of dietary leucine restriction, BCAA-free medical foods, and judicious supplementation with isoleucine and valine, with frequent clinical and biochemical monitoring. A BCAA-restricted diet fortified with prescription medical foods can maintain average plasma BCAA concentrations within standard reference intervals.

Metabolic Disease Context

Chronic elevation of BCAAs causes metabolic diseases such as obesity, type 2 diabetes, and metabolic-associated fatty liver disease. The epidemiological association between elevated circulating BCAAs and insulin resistance reflects impaired catabolism in metabolically compromised individuals, not causality from dietary supplementation. Nevertheless, the dual nature of isoleucine's metabolic effects — acutely lowering blood glucose through insulin-independent mechanisms, yet associating with elevated BMI and metabolic risk at high dietary intakes — reflects biological complexity that is an active area of research.

Special Populations and Drug Interactions

Caution or medical supervision is advised during use in chronic kidney disease (CKD) stages 3–5, ALS (where high doses are contraindicated), and during L-DOPA therapy. The interaction with L-DOPA is mechanistically plausible because large neutral amino acids including isoleucine and other BCAAs compete with L-DOPA for the same transport system across the blood-brain barrier, potentially reducing its efficacy.

Absence of Upper Intake Level Data

There are no systematic clinical studies available for isoleucine in healthy populations sufficient to establish a formal tolerable upper intake level (UL). This is an acknowledged gap in the evidence base.

References

• Wikipedia — Isoleucine
• Encyclopaedia Britannica — Isoleucine
• New World Encyclopedia — Isoleucine
• Nie C et al. Novel metabolic and physiological functions of branched chain amino acids: a review. Journal of Animal Science and Biotechnology, 2017. PMC5260006
• Yu D, Richardson NE et al. The adverse metabolic effects of branched-chain amino acids are mediated by isoleucine and valine. Cell Metabolism, 2021. PMC8102360
• Branched-chain amino acids: physico-chemical properties, industrial synthesis and role in signaling, metabolism and energy production. Amino Acids, 2024. Springer Nature
• Primary Roles of Branched Chain Amino Acids (BCAAs) and Their Metabolism in Physiology and Metabolic Disorders. PMC11721030
• Mansoori et al. Branched‐chain amino acid metabolism: Pathophysiological mechanism and therapeutic intervention in metabolic diseases. Obesity Reviews, 2025
• Santos CS, Nascimento FEL. Isolated branched-chain amino acid intake and muscle protein synthesis in humans: a biochemical review. Einstein, 2019. PMC6718193
• Doi M et al. Hypoglycemic effect of isoleucine involves increased muscle glucose uptake and whole body glucose oxidation and decreased hepatic gluconeogenesis. American Journal of Physiology-Endocrinology and Metabolism, 2007
• Doi M et al. Isoleucine, a blood glucose-lowering amino acid, increases glucose uptake in rat skeletal muscle in the absence of increases in AMP-activated protein kinase activity. Journal of Nutrition, 2005. PubMed 16140883
• Nilsson M et al. Effect of orally administered isoleucine with and without glucose on insulin, glucagon and glucose concentrations in non-diabetic subjects. European e-Journal of Clinical Nutrition and Metabolism, 2008
• Effects of isoleucine on glucose uptake through enhancement of muscular GLUT1 and GLUT4. British Journal of Nutrition. Cambridge Core
• Gluud LL et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews, 2017
• Cochrane — Branched-chain amino acids improve symptoms of hepatic encephalopathy (summary)
• Branched‐chain amino acids for people with hepatic encephalopathy. PMC6481897
• Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties. PMC10237095
• Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review of Recent Clinical Studies. PMC10334138
• Dietary isoleucine content defines the metabolic and molecular response to a Western diet. PMC11185563
• Circulating Branched Chain Amino Acids and Cardiometabolic Disease. Journal of the American Heart Association
• Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. PMC5880282
• The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis. PMC9610746
• Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances. Nutrition & Diabetes, 2022
• Branched-chain amino acids in metabolic signalling and insulin resistance. PMC4424797
• Adam MP et al. Maple Syrup Urine Disease. GeneReviews. NCBI Bookshelf NBK1319
• Strauss KA et al. Maple Syrup Urine Disease. PubMed 20301495
• Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in MSUD. PMC9420908
• Examine.com — Isoleucine: Benefits, Dosage, and Side Effects
• Isoleucine increases muscle mass through promoting myogenesis and intramyocellular fat deposition. Food & Function, RSC Publishing, 2021
• Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes. PMC5828558